$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective
Executive Summary
Luxturna, a one-time treatment for a rare inherited form of blindness, would not be cost-effective at the $1m price level that has been suggested as a possibility, based on ICER's thresholds. But the small patient population would keep it from triggering ICER's US budget spending threshold.
You may also be interested in...
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.
Spark Stands By $1M Or More Price Possibility For Luxturna
Management did not disclose the pricing strategy for the gene therapy for blindness during its third quarter financial update, but did confirm that the value of the therapy is in excess of $1m per patient.
Spark's Gene Therapy Luxturna Sails Through US FDA Panel
Improvements seen in multi-luminance mobility testing in the voretigene Phase III trial were clinically meaningful, panelists said, endorsing the novel endpoint for the vision loss treatment. They also were persuaded by first-hand accounts from patients.